Table 2.
Prognostic indicators in lung cancer amenable for use in MPE.
| Index and Definition | Patient Population | Prognostic Cutoff Value | Outcome Group | Ref |
|---|---|---|---|---|
| NLR | 382 (NSCLC) |
Low: NLR < 1.5 Intermediate: 1.5 ≤ NLR < 3.5 High: NLR ≥ 3.5 |
5 yr OS: Low 76 (77) Intermediate: 172 (70) High: 22 (58) p=0.033 |
257 |
| NLR | 88 (advanced NSCLC) |
Low: NLR ≤ 4x109 High: NLR > 4x109 | Median Survival: Low 21.4 months High 6.8 months p=0.019 DCR (Week 8): Low 28 (32) High 25 (28) p=0.025 |
258 |
| NLR | 109 (advanced NSCLC) |
Low: NLR <5: High: NLR ≥5 |
Median OS (months) Pre-treatment NLR:Low: 26.4High: 25.8p = 0.1Post-treatment NLR:Low: 29.1 High: 24.2p<0.001 | 259 |
| SII | 183 Low 149 High (NSCLC) |
660 × 109 | CR (PR): Low 76 (77) High 73 (62) SD (PD): Low 23 (23) High 45 (38) p<0.018 Median OS (months): Low 30 High 10 p<0.001 |
108 |
| SII | 140 Low: 71 male 69 female 270 High: 196 male 74 female (NSCLC) |
395.4 × 109 | Male 5 yr % OS: Low (53.4) High (35.4) p<0.0008 Female 5 yr % OS Low (63.3) High (30.9) p<0.0001 |
109 |
| SII | 214 Low 127 High (NSCLC) |
471.2 × 109 | 5 yr % OS: Low 83.61% High 60.39% p<0.0001 |
260 |
| SII ALI NLR PLR PNI |
381 (NSCLC) |
Low SII < 471.2 × 109 High SII ≥ 471.2 × 109 Low ALI ≥ 37.66 High ALI < 37.66 Low NLR < 5:1 High NLR ≥ 5:1 PLR 0 < 150:1 PLR 1 = 150 - 300 PLR 2 > 300:1 PNI 0 ≥ 45 PNI 1 < 45 |
5 yr OS (all p< 0.001): Low SII (83.61) High SII (60.39) Low ALI (57.61) High ALI (84.20) Low NLR (76.75) High NLR (40.18) PLR 0 (80.92) PLR 1-2 (62.89) PNI 0 (67.40)PNI 1 (79.01) |
261 |
| LENT | 43 Low-risk 129 Moderate-risk 31 High-risk (MPE) |
Low-risk LENT score: IQR 228–549 Moderate-risk LENT score: IQR 47–467 High-risk LENT score: IQR 22–77 |
Median survival (days) Low-risk: 319 HR (95% CI): not specified Moderate-risk: 130 HR (95% CI): 1.49 High-risk: 44 HR (95% CI): 5.97 |
110 |
| LENT | 36 High-risk 34 Moderate-risk (lung adenocarcinoma presenting with MPE) |
High-risk score: ≥ 5 Moderate-risk score: 2-4 | Median survival: High-risk: 190.5 days Moderate-risk: 346 days p<0.05 |
111 |
| PROMISE | 162 (stage IV cancer with MPE) |
Categories A: 0%-24% risk B: 25%-49% risk C: 50%-74% risk D:75%-100% risk |
3 month survival C statistic value Internal validation: 0.78 External validation: 0.89 p<0.05 |
133 |
Key: Systemic Immune-Inflammation Index (SII), Neutrophil to Lymphocyte Ratio (NLR), Non-Small Cell Lung Cancer (NSCLC), Malignant Pleural Effusion (MPE), Interquartile Range (IQR), Complete Response (CR), Partial Response (PR), Stabile Disease (SD), Progressive Disease (PD), Overall Survival (OS), Disease Control Rate (DCR), Advanced Lung Cancer Inflammation Index (ALI), Prognostic Nutritional Index (PNI), Platelet to Lymphocyte Ratio (PLR)